Colorectal Cancer: Don’t Become A StatisticEastern Biotech
All cancers, including colorectal cancer, starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancerous and can spread to other areas of the body.
Colorectal Cancer Malignancy
The rate and age dispersion of this disease differs between the majority of middle-eastern and north America and Europe for many reasons. Colorectal Cancer (CRC) is considered a standout amongst the most preventable malignancies, since it develops through polyps, in addition to one’s genetic predisposition, which become very well-known during the detection of this disease. Studies in the United Arab Emirates showed an average incidence of CRC to be 51 years and because of the rise of this cancer, a program of screening for CRC started in 2013 in Abu Dhabi for people between the ages of 40-75 years.
Control And Prevention Of Colorectal Cancer
A key part of the strategy to reduce the incidence and prevalence of colorectal cancer involves the early detection of pre-malignant lesions in the colon. Such a reduction can be achieved by the implementation of a screening program. The need for a CRC screening program was identified as part of an exercise carried out by the Health Authority of Abu Dhabi in 2010. Pilot studies in the UAE in the previous 5-10 years have demonstrated that the average age of incidence of CRC was 51 years. A multidisciplinary team was created, and global best practice was reviewed, evaluated, and assessed in order to create a program that would suit the local situation.
In 2012, colorectal cancer was the 3rd most common cancer in the UAE with 41%, and the 2nd most common cancer in men at 59% of cases.
Modifiable Risk Factors
Obesity, a diet high in fat and red meat and low in fruits and vegetables, low levels of physical activity (sedentary lifestyle), tobacco use (cigarettes, shisha and medwakh, etc.), alcohol consumption, all contribute to a higher risk of developing CRC. Changing or eliminating these habits from your lifestyle reduce your risks significantly.
Eastern Biotech Tests
- The Colorectal Cancer Focus Panel examines 17 genes associated with an increased risk for hereditary colorectal cancer. Red flags for hereditary colorectal cancer could include onset of cancer prior to the age of 50 years, more than one primary cancer in a single person, and multiple affected people within a family. This test is appropriate for patients with both polyposis and nonpolyposis colorectal cancer.
- InSure®FIT™, a CLIA waived test is available for Physician Office Lab (POL) testing. To help improve colorectal cancer screening compliance, InSure®FIT™ screening test offers high sensitivity and ease of use. It is a highly patient-friendly water-based collection method. InSure® FIT™ has 87% sensitivity for colorectal cancer & 98% specificity. The test has a 66% increase in patient compliance versus a guaiac-based fecal occult blood test (gFOBT), based on a recent study.
Eastern Biotech & Life Sciences,
P.O. Box 212671,
Elite Business Center,
1st Floor, Office No. 108,
Al Barsha, Behind Mall of Emirates, Dubai, UAE
Phone: +9714 3255730